FDA Announces Expedited Review for Nine Experimental Drugs
The Food and Drug Administration today announced the first nine experimental drugs selected for drastically accelerated review processes, a move intended to prioritize medicines deemed vital to U.S. national interests.
The drugs under expedited review address a range of conditions, including potential treatments for vaping addiction, deafness, and pancreatic cancer, with several offering alternatives to existing, higher-priced medications. President Donald Trump specifically highlighted Pergoveris, an injectable infertility drug currently available in Europe, stating that its approval in the U.S. would help lower the costs of in-vitro fertilization treatments for American families – a key campaign promise.
Another drugmaker is set to expand U.S. manufacturing of ketamine, an anesthetic increasingly used in psychedelic therapy, under the program. The FDA aims to make approval decisions on these drugs within one to two months, a significantly faster timeline than the typical six months for priority reviews or ten months for standard reviews. This initiative builds upon existing FDA programs but grants Commissioner Dr. Marty Makary and agency officials broader discretion in selecting drugs for expedited consideration, drawing parallels to the rapid authorization process used during Operation Warp Speed.
This accelerated approval process could potentially bring life-saving treatments to market faster, but also raises questions about the thoroughness of the review process. Officials stated the agency will continue to prioritize patient safety and efficacy throughout the expedited reviews, and further announcements regarding additional drugs selected for the program are expected in the coming weeks.
